Each area is a first-class topic the agent reasons about. Adding a new area is a config change, not code.
Biological mechanisms, pathways, and causal models underlying MPN pathogenesis. Includes signaling pathways, mutation effects, cellular dysfunction, microenvironment factors.
80 pages
· 681 mentions
Therapeutic interventions for MPNs — both conventional (FDA/EMA-approved drugs, established protocols) and alternative/integrative (TCM formulas, supplements, off-label use, lifestyle interventions). Pages track efficacy, side effects, allele-burden effects, and dosing.
218 pages
· 647 mentions
Subtype-specific accumulation for ET, PV, PMF, MPN-U, CMML. Each subtype gets a wiki page tracking its specific natural history, prognostic factors, transformation risk, and emerging subtype-specific findings.
16 pages
· 870 mentions
When and whether to proceed to allogeneic stem cell transplant for MPN patients. Centers on the upstream referral / timing decision — risk stratification, who benefits, when delay causes harm — and only secondarily on the operational mechanics (conditioning, bridging, donor selection) once that decision has been made. The patient-facing question this area answers is 'should I be transplanted, and when?'
39 pages
· 142 mentions
Management of MPN-related symptoms independent of disease-modifying treatments — fatigue, pruritus, night sweats, splanchnic vein thrombosis, microvascular symptoms, splenomegaly-related issues, post-splenectomy complications. Often where alternative treatments and lifestyle interventions concentrate.
16 pages
· 247 mentions
Lifestyle factors, environmental exposures, and behavioral interventions that may affect MPN outcomes — exercise, diet, alcohol, smoking, sleep, stress, hydration, heat/altitude exposure, environmental toxins, sun exposure. Evidence base is sparser than for mechanisms or treatments; synthesis must explicitly grade evidence tier on every claim.
14 pages
· 30 mentions